8-K: Profound Medical Announces Strong Q4 Revenue Growth and Provides Full Year 2024 Results

Profound Medical reports a 108% revenue increase in Q4 2024 compared to Q4 2023, driven by recurring revenue and capital equipment sales, while also announcing an amendment to its credit agreement with CIBC.

Summary

• Profound Medical Corp. announced its Q4 and full year 2024 financial results.
• Q4 revenue reached $4.2 million, a 108% increase year-over-year.
• Recurring revenue contributed $2.7 million, while capital equipment sales accounted for $1.5 million in Q4.
• The company's net loss for Q4 was $4.9 million, an improvement from the $8.9 million loss in the same period last year.
• Full year 2024 revenue totaled $10.7 million, compared to $7.2 million in 2023.
• Recurring revenue for the year was $8.2 million, and capital equipment sales were $2.5 million.
• The net loss for the full year 2024 was $27.8 million, slightly better than the $28.3 million loss in 2023.
• Profound had $54.9 million in cash as of December 31, 2024.
• The company amended its credit agreement with CIBC, securing a revolving line of credit with an option to increase it based on revenue targets.
• An error was identified that overstated revenue by $472,000 in Q1 2024, leading to a restatement of interim financial statements.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth and improved net loss, but tempered by the restatement of financial statements and ongoing losses.

Positives

• Significant revenue growth in Q4 2024, driven by both recurring revenue and capital equipment sales.
• Improved net loss in Q4 2024 compared to the same period in the previous year.
• Successful completion of patient enrollment for the CAPTAIN trial, with data expected soon.
• Collaboration with Siemens Healthineers to expand access to the TULSA procedure.
• Amendment of the credit agreement with CIBC provides financial flexibility.
• Profound's unrestricted cash must at all times be greater of: (i) to the extent EBITDA is negative for such period, EBITDA for the most recent nine-month period or (ii) $7,500,000, reported on a monthly basis; and that revenue for the most recent reported trailing 12-month period must be 15% greater than recurring revenue for the same time period in the prior fiscal year, reported on a quarterly basis.

Negatives

• An error was identified that overstated revenue by $472,000 in Q1 2024, leading to a restatement of interim financial statements.
• The company experienced a net loss of $27.8 million for the full year 2024, although slightly improved from the previous year.
• Total operating expenses increased to $40.1 million in 2024, primarily due to increased headcount and R&D investments.

Risks

• The company's ability to achieve the minimum trailing 12-month revenue of $15,000,000 to exercise the option to increase the revolving commitment by $5,000,000.
• The risk that CIBC may not approve a one-time increase in the principal amount of the revolving line of credit up to $10,000,000.
• The company's ability to maintain unrestricted cash greater than the specified thresholds under the Credit Agreement.
• The risk that revenue for the most recent reported trailing 12-month period may not be 15% greater than recurring revenue for the same time period in the prior fiscal year.
• The company's ability to successfully commercialize TULSA-PRO and Sonalleve in various markets.
• The risk of unforeseen issues arising from the transition to U.S. GAAP and the restatement of financial statements.

Future Outlook

Profound anticipates escalating growth due to TULSA procedure reimbursement and initial data readouts from the CAPTAIN clinical trial.

Management Comments

• Arun Menawat, Profound's CEO and Chairman, stated that 2024 marked the final year operating in a primarily patient-pay environment for TULSA.
• Menawat believes the company is entering a stage of anticipated escalating growth due to reimbursement and CAPTAIN trial data.

Industry Context

The collaboration with Siemens Healthineers is a strategic move to expand the reach of the TULSA procedure, potentially increasing its adoption among physicians and patients. The focus on prostate cancer and BPH treatments aligns with the growing demand for minimally invasive procedures in urology.

Comparison to Industry Standards

• Comparing Profound Medical to companies like EDAP TMS, which also focuses on minimally invasive urological treatments, Profound's revenue growth in Q4 2024 indicates a strong market position.
• The CAPTAIN trial is a Level 1 trial, which is the highest level of evidence in clinical research, suggesting a commitment to rigorous scientific validation of the TULSA procedure.
• The collaboration with Siemens Healthineers is similar to other partnerships in the medical device industry, such as Medtronic's collaborations with various hospitals and research institutions to advance medical technology.

Management Changes

Stakeholder Impact

• Shareholders may be positively impacted by the revenue growth and improved financial performance.
• Employees may benefit from the company's growth and expansion.
• Customers (physicians and patients) may benefit from the expanded access to the TULSA procedure through the collaboration with Siemens Healthineers.
• Creditors may view the amended credit agreement as a positive sign of the company's financial stability.

Next Steps

• Release of perioperative data from the CAPTAIN trial at the AUA 2025 meeting.
• Filing of restated interim financial statements for 2024.
• Continued commercialization of TULSA-PRO and Sonalleve.
• Pursuing the option to increase the revolving line of credit with CIBC.

Key Dates